Kathleen M Buchheit1, Katherine N Cahill2, Howard R Katz2, Katherine C Murphy3, Chunli Feng3, Kathleen Lee-Sarwar4, Juying Lai3, Neil Bhattacharyya5, Elliot Israel6, Joshua A Boyce2, Tanya M Laidlaw2. 1. Department of Medicine, Harvard Medical School, Boston, Mass; Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass. Electronic address: kbuchheit@partners.org. 2. Department of Medicine, Harvard Medical School, Boston, Mass; Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass. 3. Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass. 4. Department of Medicine, Harvard Medical School, Boston, Mass. 5. Department of Surgery, Harvard Medical School, Boston, Mass; Division of Otolaryngology, Brigham and Women's Hospital, Boston, Mass. 6. Department of Medicine, Harvard Medical School, Boston, Mass; Division of Pulmonary Medicine, Brigham and Women's Hospital, Boston, Mass.
Abstract
BACKGROUND: Prostaglandin (PG) D2 is the dominant COX product of mast cells and is an effector of aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease (AERD). OBJECTIVE: We evaluated the role of the innate cytokine thymic stromal lymphopoietin (TSLP) acting on mast cells to generate PGD2 and facilitate tissue eosinophilia and nasal polyposis in patients with AERD. METHODS: Urinary eicosanoid levels were measured in aspirin-tolerant control subjects and patients with AERD. Nasal polyp specimens from patients with AERD and chronic rhinosinusitis were analyzed by using quantitative PCR, Western blotting, and immunohistochemistry. Human cord blood-and peripheral blood-derived mast cells were stimulated with TSLP in vitro to assess PGD2 generation. RESULTS: Urinary levels of a stable PGD2 metabolite (uPGD-M) were 2-fold higher in patients with AERD relative to those in control subjects and increased further during aspirin-induced reactions. Peak uPGD-M levels during aspirin reactions correlated with reductions in blood eosinophil counts and lung function and increases in nasal congestion. Mast cells sorted from nasal polyps expressed PGD2 synthase (hematopoietic PGD2 synthase) mRNA at higher levels than did eosinophils from the same tissue. Whole nasal polyp TSLP mRNA expression correlated strongly with mRNA encoding hematopoietic PGD2 synthase (r = .75), the mast cell-specific marker carboxypeptidase A3 (r = .74), and uPGD-M (r = 0.74). Levels of the cleaved active form of TSLP were increased in nasal polyps from patients with AERD relative to those in aspirin-tolerant control subjects. Recombinant TSLP induced PGD2 generation by cultured human mast cells. CONCLUSIONS: Our study demonstrates that mast cell-derived PGD2 is a major effector of type 2 immune responses driven by TSLP and suggests that dysregulation of this innate system contributes significantly to the pathophysiology of AERD.
BACKGROUND:Prostaglandin (PG) D2 is the dominant COX product of mast cells and is an effector of aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease (AERD). OBJECTIVE: We evaluated the role of the innate cytokine thymic stromal lymphopoietin (TSLP) acting on mast cells to generate PGD2 and facilitate tissue eosinophilia and nasal polyposis in patients with AERD. METHODS: Urinary eicosanoid levels were measured in aspirin-tolerant control subjects and patients with AERD. Nasal polyp specimens from patients with AERD and chronic rhinosinusitis were analyzed by using quantitative PCR, Western blotting, and immunohistochemistry. Human cord blood-and peripheral blood-derived mast cells were stimulated with TSLP in vitro to assess PGD2 generation. RESULTS: Urinary levels of a stable PGD2 metabolite (uPGD-M) were 2-fold higher in patients with AERD relative to those in control subjects and increased further during aspirin-induced reactions. Peak uPGD-M levels during aspirin reactions correlated with reductions in blood eosinophil counts and lung function and increases in nasal congestion. Mast cells sorted from nasal polyps expressed PGD2 synthase (hematopoietic PGD2 synthase) mRNA at higher levels than did eosinophils from the same tissue. Whole nasal polyp TSLP mRNA expression correlated strongly with mRNA encoding hematopoietic PGD2 synthase (r = .75), the mast cell-specific marker carboxypeptidase A3 (r = .74), and uPGD-M (r = 0.74). Levels of the cleaved active form of TSLP were increased in nasal polyps from patients with AERD relative to those in aspirin-tolerant control subjects. Recombinant TSLP induced PGD2 generation by cultured human mast cells. CONCLUSIONS: Our study demonstrates that mast cell-derived PGD2 is a major effector of type 2 immune responses driven by TSLP and suggests that dysregulation of this innate system contributes significantly to the pathophysiology of AERD.
Authors: Y Kanaoka; H Ago; E Inagaki; T Nanayama; M Miyano; R Kikuno; Y Fujii; N Eguchi; H Toh; Y Urade; O Hayaishi Journal: Cell Date: 1997-09-19 Impact factor: 41.582
Authors: Gail M Gauvreau; Paul M O'Byrne; Louis-Philippe Boulet; Ying Wang; Donald Cockcroft; Jeannette Bigler; J Mark FitzGerald; Michael Boedigheimer; Beth E Davis; Clapton Dias; Kevin S Gorski; Lynn Smith; Edgar Bautista; Michael R Comeau; Richard Leigh; Jane R Parnes Journal: N Engl J Med Date: 2014-05-20 Impact factor: 91.245
Authors: June H Lee; Tmirah Haselkorn; Larry Borish; Lawrence Rasouliyan; Bradley E Chipps; Sally E Wenzel Journal: Chest Date: 2007-12 Impact factor: 9.410
Authors: Mario Noti; Elia D Tait Wojno; Brian S Kim; Mark C Siracusa; Paul R Giacomin; Meera G Nair; Alain J Benitez; Kathryn R Ruymann; Amanda B Muir; David A Hill; Kudakwashe R Chikwava; Amin E Moghaddam; Quentin J Sattentau; Aneesh Alex; Chao Zhou; Jennifer H Yearley; Paul Menard-Katcher; Masato Kubo; Kazushige Obata-Ninomiya; Hajime Karasuyama; Michael R Comeau; Terri Brown-Whitehorn; Rene de Waal Malefyt; Patrick M Sleiman; Hakon Hakonarson; Antonella Cianferoni; Gary W Falk; Mei-Lun Wang; Jonathan M Spergel; David Artis Journal: Nat Med Date: 2013-07-21 Impact factor: 53.440
Authors: A R Fischer; M A Rosenberg; C M Lilly; J C Callery; P Rubin; J Cohn; M V White; Y Igarashi; M A Kaliner; J M Drazen Journal: J Allergy Clin Immunol Date: 1994-12 Impact factor: 10.793
Authors: Elina Jerschow; Matthew L Edin; Teresa Pelletier; Waleed M Abuzeid; Nadeem A Akbar; Marc Gibber; Marvin Fried; Fred B Lih; Artiom Gruzdev; J Alyce Bradbury; Weiguo Han; Golda Hudes; Taha Keskin; Victor L Schuster; Simon Spivack; Darryl C Zeldin; David Rosenstreich Journal: J Allergy Clin Immunol Pract Date: 2017-01-31
Authors: Sean J Lund; Alex Portillo; Kellen Cavagnero; Rachel E Baum; Luay H Naji; Jana H Badrani; Amit Mehta; Michael Croft; David H Broide; Taylor A Doherty Journal: J Immunol Date: 2017-06-30 Impact factor: 5.422
Authors: Elina Jerschow; Matthew L Edin; Yuling Chi; Beth Hurst; Waleed M Abuzeid; Nadeem A Akbar; Marc Gibber; Marvin P Fried; Weiguo Han; Teresa Pelletier; Zhen Ren; Taha Keskin; Gigia Roizen; Fred B Lih; Artiom Gruzdev; J Alyce Bradbury; Victor Schuster; Simon Spivack; David Rosenstreich; Darryl C Zeldin Journal: J Allergy Clin Immunol Pract Date: 2018-12-21
Authors: Jacqueline J Eastman; Kellen J Cavagnero; Adam S Deconde; Alex S Kim; Maya R Karta; David H Broide; Bruce L Zuraw; Andrew A White; Sandra C Christiansen; Taylor A Doherty Journal: J Allergy Clin Immunol Date: 2017-03-06 Impact factor: 10.793
Authors: Kathleen M Buchheit; Daniel F Dwyer; Jose Ordovas-Montanes; Howard R Katz; Erin Lewis; Marko Vukovic; Juying Lai; Lora G Bankova; Neil Bhattacharyya; Alex K Shalek; Nora A Barrett; Joshua A Boyce; Tanya M Laidlaw Journal: J Allergy Clin Immunol Date: 2020-03-19 Impact factor: 10.793